Navigation Links
Schering-Plough CEO Buys $2 Million in Common Shares
Date:4/24/2008

KENILWORTH, N.J., April 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that Chairman and CEO Fred Hassan purchased just over $2 million of Schering-Plough common stock, or 110, 000 shares at an average purchase price of $18.26 per share.

"As I said when I announced my intention to purchase these shares in January, this investment in Schering-Plough reflects my long-term confidence in the company, its products -- including ZETIA and VYTORIN -- and our late- stage pipeline," said Hassan.

Hassan has said on January 18 that he intended to purchase the shares as soon as the transaction received legal clearance. That clearance was issued this morning, based upon first quarter earnings having been reported yesterday.

Full details of the purchase will be reported on a Form 4 filed with the SEC and available on Schering-Plough's Web site today or tomorrow.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
2. Schering-Plough Reports Financial Results for First Quarter of 2008
3. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
4. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
5. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
7. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
8. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
9. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
10. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
11. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...RNewswire-USNewswire/ -- The Michael J. Fox Founda...ed $1.5 million in total awards to six research te...ng therapies for Parkinson,s disease. The funding ...scovery for Parkinson,s Disease program, made pos... ELN ), a neuroscience-based biotechnology compa...
(Date:11/30/2009)...ber 30 Biopharmaceutical company K...ts have been enrolled in its,multinational registr...esigned to show reduction in transplant related mo...ic stem cell transplantation with a mismatched,(ha...ible for an allogeneic,stem cell transplantation b...
(Date:11/30/2009)... 30 Novavax, Inc. (Nasda...ment in the Phase II clinical study of its trivale...ns) VLP vaccine candidate in healthy adults 60 yea...d, double-blind, active-controlled study is compar... two different doses (15 mcg and 60 mcg) of Novava...
(Date:11/30/2009)...0 Cell Therapeutics, Inc...t its new class of platinum-based anti-tumor compo...er anti-tumor potency and activity compared to cur...as the ability to overcome cisplatin-resistance in... a paper titled "Novel Bis-platinum Complexes Endo...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
... - Deriving plentiful electricity from sunlight at...tions for energy, technology, and climate policy. ...ss , the Optical Society,s (OSA) open-access journ...ells: lacing them with nanoscopic metal particles....oach has the potential to greatly improve the abil...
... International supplier of animal free, produc...ers its customers the chance to improve performanc..., Fort Collins, CO (PRWEB)...nference, hosted by the Williamsburg BioProcessing...research data of InVitria , a company committed t...
...e University and United States Army scientists hav...er rash preventative can be made to produce brilli...junct physics professor Henry Everitt, chemistry p...oreman have discovered that adding sulfur to ultra...,000 degrees centigrade allows the preparation to ...
Other Biology Technology:Enhancing solar cells with nanoparticles 2InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting 2Duke researchers coax bright white light from unexpected source 2Duke researchers coax bright white light from unexpected source 3
(Date:11/30/2009)...nsive review of the state of Antarctica,s climate ...is published this week (Tuesday 1 December) by the.... The review - Antarctic Climate Change and the E...icy continent, identifies areas for future scienti...hat policy makers have about Antarctic melting, se...
(Date:11/30/2009)...vailable in German . , The DFG has approved...h Centres as of 1 January 2010. This decision was ...Bonn. The new centres will initially be funded for...on, 20 percent overhead funding for indirect costs...es, research topics range from modern prostheses t...
(Date:11/30/2009)...sion proteins are crucial for infection. Each bind...s, which stimulates the host cell to take up the p...a different function, for example the regulation o...ts have now been published in the current issue of... meat is one of the sources for Listeria infecti...
Breaking Biology News(10 mins):First comprehensive review of the state of Antarctica's climate 2DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9It takes 2 to infect 2Masimo to Report Second Quarter 2009 Financial Results on August 4 2009 52366 1Masimo to Report Second Quarter 2009 Financial Results on August 4 2009 52366 2Masimo to Report Second Quarter 2009 Financial Results on August 4 2009 52366 3Following CMS Cuts to Reimbursement for Medical Errors New Devices Aimed at Reducing Nosocomial Infections Emerge 52363 1Following CMS Cuts to Reimbursement for Medical Errors New Devices Aimed at Reducing Nosocomial Infections Emerge 52363 2Following CMS Cuts to Reimbursement for Medical Errors New Devices Aimed at Reducing Nosocomial Infections Emerge 52363 3University of Lodz Invests in the Unique Cellaxess 28R 29HT System for Research on Multidrug Resistance Genes in Cancer 13140 1University of Lodz Invests in the Unique Cellaxess 28R 29HT System for Research on Multidrug Resistance Genes in Cancer 13140 2
... Biology Laboratory (EMBL) in Heidelberg, Germany,...MBL-EBI) in Hinxton, UK, have revealed new insight...tin modifying enzyme helps compensate for the fact...me X, while females have two. The enzyme distingui...uit flies and binds to different locations on the ...
...ether to announce funding for new projects designe...in the emerging field of synthetic biology. The Bi...il (BBSRC) and the Engineering and Physical Scienc...o seven new networks in synthetic biology to allow... and discipline boundaries to form a true syntheti...
...k-old peach has helped scientists zero in on a pro..., The paradoxical finding gives scientists a bett...ggshell layer forms as it points to a likely targe..., developmental biologist in the Medical College o.... , Her research team named the newly discovered ...
Other Biology News:X chromosome exposed 2New projects to raise UK profile in synthetic biology 2Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 2Fruit fly helps identify protein critical to eggshell formation that may be pesticide target 3
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
...r routine procedures. Hollandes contains formaldeh...l decalcify small bone specimens. Tissue that is f...ith most stains, and the cupric acetate in the sol...nophil and endocrine cell granules so that less ly...
...tograph/Mass Spectrometer, utilizing many of the h...igh throughput and excellent productivity, providi...io. Like the GCMS-QP2010 Plus, the GCMS-QP2010s fe...um separation, 20 temperature ramps, and both scan...
Biology Products: